INOVIQ Ltd
INOVIQ Ltd
Your view on IIQ.AX
Overview
What the company does, where it operates, and who runs it.
About INOVIQ Ltd
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Leearne Maree Hinch
- Headquarters
- 23 Normanby Road, Notting Hill, VIC, AU
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Leearne Maree Hinch
- Headquarters
- 23 Normanby Road, Notting Hill, VIC, AU
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States.
Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens.
The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer.
Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for INOVIQ Ltd. Starting points for INOVIQ Ltd: EPS -AUD 0.05, beta 1.62 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for INOVIQ Ltd. INOVIQ Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for INOVIQ Ltd. Trailing twelve-month EPS for INOVIQ Ltd stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterMar 2026 | Next quarterJun 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | AUD 0.00 | −AUD 0.07 | −AUD 0.06 |
| Lowest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.10 | −AUD 0.14 |
| Highest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.05 | AUD 0.02 |
| Number of analysts | 0 | 0 | 1 | 2 |
| A year ago | — | — | −AUD 0.06 | — |
| Growth vs a year ago | — | — | −28.3% | — |
Revenue estimates
| Total | This quarterMar 2026 | Next quarterJun 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 242760.00 | AUD 202463.00 | AUD 5.70M | AUD 9.40M |
| Lowest estimate | AUD 242760.00 | AUD 202463.00 | AUD 4.07M | AUD 8.66M |
| Highest estimate | AUD 242760.00 | AUD 202463.00 | AUD 7.33M | AUD 10.14M |
| Number of analysts | 1 | 1 | 1 | 2 |
| A year ago | — | — | AUD 432047.00 | — |
| Growth vs a year ago | — | — | +1219.3% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for INOVIQ Ltd. INOVIQ Ltd has reported as a listed company since 1988. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| BDX.AXBCAL Diagnostics Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| EMD.AXEmyria Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| EYE.AXNova Eye Medical Limited | Healthcare | Medical - Devices | — | ||
| LGP.AXLittle Green Pharma Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| MAP.AXMicroba Life Sciences Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| WUXIFWuXi AppTec Co., Ltd. | Healthcare | OTC | $39.8B | ||
| XGNExagen Inc. | Healthcare | NASDAQ | $92.1M | ||
| SKHHYSonic Healthcare Limited | Healthcare | OTC | $8.2B | ||
| SLDXStella Diagnostics Inc. | Healthcare | OTC | $1.4M | ||
| SPDESpeedus Corp. | Healthcare | OTC | $416 | ||
| SZLSFStageZero Life Sciences Ltd. | Healthcare | OTC | $61,766 | ||
| TDSGFTelo Genomics Corp. | Healthcare | OTC | $3.8M | ||
| TELO.VTelo Genomics Corp. | Healthcare | TSXV | $4.0M | ||
| THOXFBioPorto A/S | Healthcare | OTC | $73.8M | ||
| TMOThermo Fisher Scientific Inc. | Healthcare | NYSE | $248.1B | ||
| TMO.NEThermo Fisher Scientific Inc. | Healthcare | NEO | — | ||
| TOMDFTodos Medical Ltd. | Healthcare | OTC | $14,081 | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of INOVIQ Ltd.